High-sensitive cardiac troponin T as a predictor of efficacy and safety after pulmonary vein isolation using focal radiofrequency, multielectrode radiofrequency and cryoballoon ablation catheter.
ablation
atrial fibrillation
complications
creatine kinase
creatine kinase-mb
cryoballoon
high-sensitive-troponin T
nmarq
pericarditis
pulmonary vein isolation
radiofrequency
recurrence
Journal
Open heart
ISSN: 2053-3624
Titre abrégé: Open Heart
Pays: England
ID NLM: 101631219
Informations de publication
Date de publication:
Historique:
received:
14
10
2018
revised:
26
02
2019
accepted:
19
03
2019
entrez:
7
6
2019
pubmed:
7
6
2019
medline:
7
6
2019
Statut:
epublish
Résumé
Myocardial injury markers such as high-sensitive cardiac troponin T (hs-cTnT) and creatine kinase MB (CK-MB) reflects the amount of myocardial injury with ablation. The aim of the study was to identify the value of myocardial injury markers to predict outcomes after pulmonary vein isolation (PVI) using three different ablation technologies. Consecutive patients undergoing PVI using a standard 3.5 mm irrigated-tip radiofrequency catheter (RF-group), an irrigated multielectrode radiofrequency catheter (IMEA-group) and a second-generation cryoballoon (CB-group) were analysed. Blood samples to measure injury markers were taken before and 18-24 hours after the ablation. Procedural complications were collected and standardised follow-up was performed. Logistic regression was used to identify predictors of recurrence and complications. 96 patients (RF group: n=40, IMEA-group: n=17, CB-group: n=39) undergoing PVI only were analysed (82% male, age 59±10 years). After a follow-up of 12 months, atrial fibrillation (AF) recurred in 45% in the RF-group, 29% in the IMEA-group and 36% in the CB-group (p=0.492). Symptomatic pericarditis was observed in 20% of patients in the RF-group, 15% in the IMEA-group and 5% in the CB-group (p=0.131). None of the injury markers was predictive of AF recurrence or PV reconnection after a single procedure. However, hs-cTnT was identified as a predictor of symptomatic pericarditis (OR: 1.003 [1.001 to 1.005], p=0.015). Hs-cTnT and CK-MB were significantly elevated after PVI, irrespective of the ablation technology used. None of the myocardial injury markers were predictive for AF recurrence or PV reconnection, but hs-cTnT release predicts the occurrence of symptomatic pericarditis after PVI.
Identifiants
pubmed: 31168374
doi: 10.1136/openhrt-2018-000949
pii: openhrt-2018-000949
pmc: PMC6519429
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e000949Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Indian Heart J. 1999 Jul-Aug;51(4):418-21
pubmed: 10547941
Heart Rhythm. 2010 Dec;7(12):1770-6
pubmed: 20817019
Rev Esp Cardiol. 2011 Feb;64(2):127-32
pubmed: 21237551
Int J Cardiol. 2012 Jun 28;158(1):33-8
pubmed: 21276621
Heart Rhythm. 2012 Feb;9(2):189-96
pubmed: 21920484
Heart Rhythm. 2012 Apr;9(4):632-696.e21
pubmed: 22386883
Europace. 2013 Nov;15(11):1567-73
pubmed: 23703361
Cardiol J. 2013;20(3):294-303
pubmed: 23788304
Heart Rhythm. 2014 Jan;11(1):8-14
pubmed: 24103221
Cardiol J. 2014;21(5):516-23
pubmed: 24293166
Circ Arrhythm Electrophysiol. 2014 Feb;7(1):83-9
pubmed: 24446024
Europace. 2014 Jul;16(7):987-93
pubmed: 24446511
Europace. 2014 Aug;16(8):1154-9
pubmed: 25074972
J Cardiovasc Electrophysiol. 2015 Apr;26(4):397-403
pubmed: 25588685
Europace. 2016 Jan;18(1):85-91
pubmed: 25883078
Circ Arrhythm Electrophysiol. 2015 Aug;8(4):836-45
pubmed: 26082516
Eur Heart J. 2015 Nov 7;36(42):2921-2964
pubmed: 26320112
Circ J. 2016;80(2):346-53
pubmed: 26638872
J Cardiovasc Electrophysiol. 2016 Apr;27(4):381-9
pubmed: 26786052
J Cardiovasc Electrophysiol. 2016 May;27(5):602-8
pubmed: 26856381
Cardiovasc Ther. 2016 Jun;34(3):144-51
pubmed: 26880220
J Interv Card Electrophysiol. 2016 Oct;47(1):69-74
pubmed: 26971332
Ann Clin Biochem. 2017 Jan;54(1):121-126
pubmed: 27166316
Heart Rhythm. 2016 Sep;13(9):1852-7
pubmed: 27241352
Clin Chem. 2016 Aug;62(8):1106-14
pubmed: 27335076
Eur Heart J. 2016 Oct 07;37(38):2858-2865
pubmed: 27381589
Europace. 2017 Dec 1;19(12):1951-1957
pubmed: 28069837
Biomarkers. 2017 Dec;22(8):701-708
pubmed: 28545334
J Cardiovasc Electrophysiol. 2017 Nov;28(11):1247-1256
pubmed: 28800169
J Am Coll Cardiol. 2017 Aug 22;70(8):996-1012
pubmed: 28818210
Europace. 2018 Aug 1;20(8):1279-1286
pubmed: 29016870
Biomarkers. 2018 Sep;23(6):512-517
pubmed: 29631448
Heart Vessels. 2019 Mar;34(3):509-516
pubmed: 30182157
Trends Cardiovasc Med. 2018 Nov 16;:null
pubmed: 30552043